Banco de Sabadell S.A Purchases 34,845 Shares of Pfizer Inc. (NYSE:PFE)

Banco de Sabadell S.A lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 94.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,860 shares of the biopharmaceutical company's stock after acquiring an additional 34,845 shares during the period. Banco de Sabadell S.A's holdings in Pfizer were worth $2,064,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Clifford Swan Investment Counsel LLC grew its position in Pfizer by 4.7% in the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company's stock worth $12,007,000 after purchasing an additional 18,611 shares during the period. Adage Capital Partners GP L.L.C. grew its position in Pfizer by 40.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company's stock worth $157,215,000 after purchasing an additional 1,365,295 shares during the period. LifePlan Financial LLC bought a new stake in Pfizer in the 4th quarter worth approximately $255,000. KLCM Advisors Inc. grew its position in Pfizer by 75.0% in the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company's stock worth $5,004,000 after purchasing an additional 74,487 shares during the period. Finally, Farmers Trust Co. grew its position in Pfizer by 2.0% in the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company's stock worth $6,503,000 after purchasing an additional 4,410 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

PFE stock traded up $1.04 during mid-day trading on Wednesday, hitting $29.60. The company had a trading volume of 46,109,194 shares, compared to its average volume of 42,566,008. The company has a market capitalization of $167.73 billion, a price-to-earnings ratio of -493.25, a P/E/G ratio of 1.20 and a beta of 0.63. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average price of $27.22 and a 200 day moving average price of $27.96.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analysts' expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business's quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.23 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.39 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.68%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer's dividend payout ratio is -2,799.53%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on PFE shares. Morgan Stanley boosted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an "equal weight" rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. BMO Capital Markets reissued an "outperform" rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Argus downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. Finally, Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a "buy" rating and a $36.00 price objective for the company. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.